When did Amneal Pharmaceuticals, Inc. report Q4 2024 earnings?

Amneal Pharmaceuticals, Inc. (AMRX) reported Q4 2024 earnings on February 28, 2025 before market open.

What were Amneal Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?

Amneal Pharmaceuticals, Inc. reported revenue of $730.5M and eps of $0.12 for Q4 2024.

Did Amneal Pharmaceuticals, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $723.1M by $7.4M. EPS missed the consensus estimate of $0.15 by $0.03.

Where can I find Amneal Pharmaceuticals, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001723128-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.

Amneal Pharmaceuticals, Inc. AMRX Q4 2024 Annual earnings

Reported February 28, 2025 · Before market open

Revenue$730.5MBeat by $7.4M

EPS$0.12Miss by $0.03

Revenue estimate$723.1M

EPS estimate$0.15

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$768.2M

EPS estimate$0.24

Financials

Q4 2024

Income statement

See full

Revenue$730.5M+18.4%

Gross profit$262.9M+38.5%

Operating income$75.8M+434%

Net income-$31.1M+68.5%

EPS (diluted)-$0.10+82.5%

Balance sheet

See full

Cash & equivalents$110.6M+20.8%

Total debt$2.5B-1.5%

Total equity-$109.3M-652%

Total assets$3.5B+0.8%

Cash flow

See full

Operating cash flow$118.1M-13.1%

CapEx$15.2M+53.6%

Free cash flow$102.9M-18.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2.45B+31.9%

Enterprise value$4.84B+12.5%

P/S0.9×+0.1×

Profitability

See full

Gross margin36.5%+2.2pp

Operating margin8.9%+0.4pp

Net margin-4.2%+1.0pp

FCF margin8.7%-4.9pp

Returns & leverage

See full

Current ratio1.4×-0.2×

Segments

By product

See full

Subtotal dosage forms$438.0M—

Oral solid$183.0M—

Subtotal therapeutic classes$120.8M—

Distribution$106.5M+8.2%

Central nervous system$76.6M—

By segment

See full

Affordable Medicines$439.3M—

AvKARE$170.4M+14.0%

Specialty$120.8M+15.7%

Versus estimates

Revenue

Q1 2026$722.5MBeat by $2.9M Q4 2025$814.3MBeat by $7.0M Q3 2025$784.5MMiss by $21.6M Q2 2025$724.5MMiss by $44.1M Q1 2025$695.4MMiss by $48.8M

Q4 2024$730.5MBeat by $7.4M

Diluted EPS

Q1 2026$0.27Beat by $0.10 Q4 2025$0.21Beat by $0.03 Q3 2025$0.17Beat by $0.04 Q2 2025$0.25Beat by $0.07 Q1 2025$0.21Beat by $0.06

Q4 2024$0.12Miss by $0.03

Ask the moment Amneal Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Amneal Pharmaceuticals, Inc. report Q4 2024 earnings?: Amneal Pharmaceuticals, Inc. (AMRX) reported Q4 2024 earnings on February 28, 2025 before market open.
What were Amneal Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?: Amneal Pharmaceuticals, Inc. reported revenue of $730.5M and eps of $0.12 for Q4 2024.
Did Amneal Pharmaceuticals, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $723.1M by $7.4M. EPS missed the consensus estimate of $0.15 by $0.03.
Where can I find Amneal Pharmaceuticals, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001723128-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.